Abzena introduces novel platforms for cell line development

Abzena has recently introduced the AbZelect platforms, which are aimed at enhancing cell line development

On January 16, 2023, Abzena introduced AbZelect and AbZelectPRO, their latest cell line development platforms. These platforms are specifically designed to accelerate the creation of production cell lines used in the production of antibodies and recombinant proteins. The platforms are designed to facilitate the efficient advancement of intricate biologic drug programs towards clinical trials and the filing of investigational new drug (IND) applications.
As per a company press release, the CLD platforms allow for the quick creation and selection of productive mammalian Chinese hamster ovary cell lines for the production of therapeutic proteins and recombinant vaccines. AbZelect is well-suited for conventional protein applications, like antibodies. According to this design, it has been optimized in three important areas: vector, host cell line, and process.
AbZelectPRO utilizes the powerful combination of AbZelect and ProteoNic Biosciences' 2G UNic vector technology. This innovative approach enhances expression levels and creates more productive and reliable cell lines. These cell lines are capable of expressing a wide range of proteins, including bispecifics, fusion proteins, and other exciting new modalities. This information was shared in a recent press release. These platforms aim to streamline the process from DNA to research cell banks, reducing the timeline to just 15 weeks.
The increased productivity offered by the AbZelect and AbZelectPRO platforms allows for higher production of drug substances per manufacturing run. Matthew Stober, CEO of Abzena, expressed his enthusiasm for the efficiencies that will not only increase capacity and lower costs for customers but also expedite the delivery of vital therapies to patients in need.

Source: Abzena